Niels Plath, PhD, Muna Therapeutics, Copenhagen, Denmark, discusses recent developments in microglial and inflammatory biomarkers of Alzheimer’s disease (AD). There are currently some promising biomarker candidates, however it is critical for the field that these ideas are validated, not only in research models but also in human patients. These include imaging biomarkers of microglia reactivity, as well as cerebrospinal fluid and plasma levels of inflammatory proteins. An exciting recent development is the use of microvesicles that can be harvested from the blood but reflect centrally mediated immune activity. This interview took place at the Alzheimer’s Association International Conference (AAIC) 2022 in San Diego, CA.
Disclosures
Niels Plath is a full time employee at Muna Therapeutics.
